Dr. Michael B. Denenberg, M.D.
Pulmonology (Pulmonary Disease Physician)
370 South Herlong Avenue, Suite 200
Rock Hill, SC 29732
Who else practices at this address →
York County includes primary care (100% of residents) and mental health (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- R Franklin University of Med & Sci/Chicago Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 913
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: R Franklin University of Med & Sci/Chicago Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
SC license MD21599 -
Sleep Medicine (Internal Medicine) Physician
SC license MD21599
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Medical Center Rock Hill, SC
Medical groups
- Southeast Pulmonary and Critical Care LLC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 913
- Services billed
- 3,269
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 755 | 166 |
| Established patient office or other outpatient visit, 30-39 minutes | 558 | 362 |
| Test to measure expiratory airflow and volume | 533 | 454 |
| Established patient office or other outpatient visit, 20-29 minutes | 432 | 370 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 162 | 145 |
| New patient office or other outpatient visit, 45-59 minutes | 158 | 158 |
| Test to measure the level of nitric oxide gas | 116 | 111 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 88 | 88 |
| Established patient office or other outpatient visit, 10-19 minutes | 78 | 76 |
| Test for exercise-induced lung stress | 60 | 55 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Rock Hill, SC | 484 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Rock Hill, SC | 439 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Rock Hill, SC | 290 |
| Prednisone Other prescribers in Rock Hill, SC | 283 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Rock Hill, SC | 179 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Rock Hill, SC | 135 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Rock Hill, SC | 118 |
| Fluticasone Propionate Other prescribers in Rock Hill, SC | 114 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Rock Hill, SC | 113 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Rock Hill, SC | 109 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $139 in total to this clinician.
| Insmed, Inc. | $51.64 |
|---|---|
| Inspire Medical Systems, Inc. | $51.14 |
| GlaxoSmithKline, LLC. | $19.91 |
| Teva Pharmaceuticals USA, Inc. | $15.95 |
| Food and Beverage | $121 |
|---|---|
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Aug 26, 2025 | Education in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 35 industry-funded studies in 2025, from 15 companies. The companies reported $682,892 in research payments for these studies, mostly to the institutions running them.
- A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Verona Pharma, Inc. - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Pharmaceuticals USA, Inc. - Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
AstraZeneca Pharmaceuticals LP - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A two-part phase 1 randomized, double-blind, placebo-controlled study
GlaxoSmithKline, LLC. - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.